EVALUATION OF URINARY BIOMARKERS FOR THE EARLY DETECTION OF BLADDER CANCER
Main Article Content
Keywords
Bladder carcinoma, urinary bio markers, screening, NMP22
Abstract
Background: Bladder cancer is one of the most common cancers characterized by high rates of tumor recurrence throughout the patient’s life. Urine biomarkers detect the disease in its early stages to enhance patient prognosis, lower mortality and lessen expensive procedures such as cystoscopy.
Objectives: The purpose of this paper is to assess the performance of the biomarkers within urine for the early diagnosis of bladder cancer and compare the results with conventional approaches.
Study design: A Cross Sectional study
Place and duration of study. Department of General Surgery Ziauddin University Hospital from jan 2021 to dec 2021
Methods: A total of 150 patients, 90 cases with bladder cancer and 60 controls were assessed. NMP22, UroVysion, and BLCA-4 were utilized in the urinary samples with biomarkers. Diagnostic accuracy, sensitivity, and specificity of each of the markers were calculated using the test results. Quantitative descriptive data was used in statistical comparison where standard deviation (SD) and p-value were used to test the significance of the findings.
Results: The urinary biomarkers demonstrated fairly inconsistent mean sensitivities and specificities for early detection. Detectivity of NMP22 was 82% (SD ± 4.5), of UroVysion 78% (SD ± 3.2), of BLCA-4 was 85% (SD ± 5.1). The sensitivity of the tests were at 75% (SD ± 3.8) for NMP22, 82% (SD ± 4.0) for UroVysion and 80% (SD ± 4.3) for BLCA-4. The p-values for all biomarkers regarding difference in performance compared with conventional approaches were <0.05, which revealed statistical difference.
Conclusions: Several urinary markers, such as BLCA-4, have been also identified to provide the potential for early diagnosis of bladder cancer in humans. It is therefore clear that these non invasive procedures are effective, highly sensitive and specific investigations in place of cystoscopy. Additional big research trials using these deadlines still have to be conducted in order to determine their efficacy in clinical practice.
References
2. Siegel, R. L., Miller, K. D., & Jemal, A. (2020). Cancer statistics, 2020. CA: A Cancer Journal for Clinicians, 70(1), 7-30. https://doi.org/10.3322/caac.21590
3. Kamat, A. M., Hegarty, P. K., Gee, J. R., Clark, P. E., Svatek, R. S., Hegarty, N., ... & Boorjian, S. A. (2016). ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers. European Urology, 63(1), 4-15. https://doi.org/10.1016/j.eururo.2012.09.054
4. Babjuk, M., Burger, M., Compérat, E. M., Gontero, P., Mostafid, A. H., Palou, J., ... & Shariat, S. F. (2019). European Association of Urology Guidelines on non–muscle-invasive bladder cancer (TaT1 and CIS). European Urology, 76(5), 639-657. https://doi.org/10.1016/j.eururo.2019.08.016
5. Lokeshwar, V. B., Habuchi, T., Grossman, H. B., Murphy, W. M., Hautmann, S. H., Hemstreet, G. P., ... & Fradet, Y. (2005). Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology, 66(6), 35-63. https://doi.org/10.1016/j.urology.2005.07.017
6. Lotan, Y., & Roehrborn, C. G. (2003). Sensitivity and specificity of commonly available bladder tumor markers versus cytology: Results of a comprehensive literature review and meta-analyses. Urology, 61(1), 109-118. https://doi.org/10.1016/S0090-4295(02)02198-2
7. Grossman, H. B., Messing, E., Soloway, M., Tomera, K., Katz, G., Berger, Y., & Shen, Y. (2005). Detection of bladder cancer using a point-of-care proteomic assay. JAMA, 293(7), 810-816. https://doi.org/10.1001/jama.293.7.810
8. Halling, K. C., King, W., Sokolova, I. A., Karnes, R. J., Meyer, R. G., Powell, E. L., ... & Sebo, T. J. (2000). A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. The Journal of Urology, 164(5), 1768-1775. https://doi.org/10.1016/S0022-5347(05)67055-0
9. Konety, B. R., Nguyen, T. S., Dhir, R., Day, R. S., Becich, M. J., Stadler, W. M., & Getzenberg, R. H. (2000). Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4. Clinical Cancer Research, 6(7), 2618-2625.
10. Shariat, S. F., Marberger, M. J., Lotan, Y., & Sánchez-Carbayo, M. (2008). Early detection of bladder cancer: Microscopic and molecular markers. Expert Review of Anticancer Therapy, 8(7), 1131-1142. https://doi.org/10.1586/14737140.8.7.1131
11. Miyanaga, N., Akaza, H., Okamura, T., Ohtani, M., Uchida, T., Koiso, K., ... & Soloway, M. S. (1999). Urinary NMP22 and bladder cancer: A clinical evaluation. Japanese Journal of Clinical Oncology, 29(12), 604-606. https://doi.org/10.1093/jjco/29.12.604
12. Chou, R., Gore, J. L., Buckley, D., Fu, R., Gustafson, K., Griffin, J. C., & Grusing, S. (2015). Urinary biomarkers for diagnosis of bladder cancer: A systematic review and meta-analysis. Annals of Internal Medicine, 163(12), 922-931. https://doi.org/10.7326/M15-0997
13. Witjes, J. A., Morote, J., Cornel, E. B., Gakis, G., van Valenberg, F. J. P., de Jong, F. C., ... & de Reijke, T. M. (2018). Performance of the Bladder EpiCheck™ methylation test for patients under surveillance for non–muscle-invasive bladder cancer: Results of a multicenter, prospective, blinded clinical trial. European Urology Oncology, 1(4), 307-313. https://doi.org/10.1016/j.euo.2018.02.002
14. Yafi, F. A., Brimo, F., Steinberg, J., Aprikian, A. G., Tanguay, S., & Kassouf, W. (2015). Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 33(2), 66-e25. https://doi.org/10.1016/j.urolonc.2014.06.001
15. Green, D. A., Rink, M., Matin, S. F., Stenzl, A., Rouprêt, M., & Babjuk, M. (2013). Urothelial carcinoma of the bladder and the upper tract: Disparate twins. The Journal of Urology, 189(4), 1214-1221. https://doi.org/10.1016/j.juro.2012.12.030
16. O'Sullivan, P., Sharples, K., Dalphin, M., Davidson, P., Gilling, P., Cambridge, L., ... & Harris, M. (2012). A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria. The Journal of Urology, 188(3), 741-747. https://doi.org/10.1016/j.juro.2012.05.009
17. Grossman, H. B., Soloway, M., Messing, E., Katz, G., Stein, B., Kassabian, V., ... & Shen, Y. (2006). Detection of bladder cancer using a point-of-care proteomic assay. JAMA, 295(4), 299-305. https://doi.org/10.1001/jama.295.3.299
18. Getzenberg, R. H. (1996). Nuclear matrix and the regulation of gene expression: Tissue specificity. Journal of Cellular Biochemistry, 62(2), 145-148. https://doi.org/10.1002/(SICI)1097-4644(19960801)62:2%3C145::AID-JCB2%3E3.0.CO;2-7
19. Landman, J., Chang, Y., Kavaler, E., Droller, M. J., & Liu, B. C. (1998). Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology, 52(3), 398-402. https://doi.org/10.1016/S0090-4295(98)00199-6
20. Svatek, R. S., Herman, M. P., Lotan, Y., Karakiewicz, P. I., Shariat, S. F., & Dinney, C. P. (2009). The use of urinary markers in surveillance of patients with high-risk non-muscle-invasive bladder cancer: Bladder tumour markers beyond cytology. Cancer, 115(12), 2641-2650. https://doi.org/10.1002/cncr.24268
21. Babjuk, M., Böhle, A., Burger, M., Capoun, O., Cohen, D., Compérat, E. M., ... & Zigeuner, R. (2017). EAU Guidelines on non–muscle-invasive bladder cancer (TaT1 and CIS). European Urology, 71(3), 447-461. https://doi.org/10.1016/j.eururo.2016.12.038
22. van Rhijn, B. W., van der Poel, H. G., & van der Kwast, T. H. (2005). Urine markers for bladder cancer surveillance: A systematic review. European Urology, 47(6), 736-748. https://doi.org/10.1016/j.eururo.2005.01.014
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Yasir Murtaza
Assistant professor Ziauddin University Hospital, Karachi
Nadia Shahid
Associate Professor General Surgery Ziauddin Hospital Karachi
Mir Arsalan Ali
Assistant Professor, Department of General Surgery, Ziauddin University, Karachi
Muhammad Tahir
consultant surgeon surgical unit 2mAbbasi Shaheed Hospital
Aun Ali
Professor- General Surgery, Fizaia Ruth Pfao Medical College
Summaya Saeed
Associate Professor Surgery Dow Medical College/ DUHS